Treating COVID-19 infection with molnupiravir does not decrease deaths or hospital admission in high-risk, vaccinated patients, but can lead to quicker recovery

Molnupiravir (taken as an 800mg dose twice daily for five days) does not reduce hospital admissions or deaths in vaccinated adults with COVID-19 infection who are at higher risk of mortality, according to the results of a randomised controlled trial, published in The Lancet journal. However, the patients treated at home with molnupiravir recovered quicker compared to the control group. Previous studies […]